This Is MS Multiple Sclerosis Community: Knowledge & Support

Hard To Treat Diseases (HTDS.PK) Scientists Present Encouraging Results For The Future Of Multiple Sclerosis Treatment
Main Category: Multiple Sclerosis
Article Date: 15 Aug 2009 - 1:00 PDT

--------------------------------------------------------------------------------

Hard to Treat Diseases, Inc. (HTDS:PK), announced that there is great progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis not only in their lab in Belgrade, but around the world.

In a recent study posted on Aug. 12, 2009 scientists have reversed the Multiple Sclerosis in mice. The study showed the suppression of the immune cells, forcing remission and reversing the disease in mice.

Multiple Sclerosis attacks the central nervous system. The researchers explained that "The new treatment, called GIFT15, is composed of two proteins, GSM-CSF and interleukin-15, that are fused in the lab. Normally, the individual proteins act to stimulate the immune system, but when they're stuck together, the proteins suppress immune response, the researchers explained. They do this by converting B-cells -- a type of white blood cell normally involved in immune response -- into immune suppressive cells."

Dr. Jacques Galipeau and his collegues of the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal, took normal B-cells from mice and sprinkled GIFT-15 on the B-cells and when this was given in a single dose intravenously back to the mice that were ill with Multiple sclerosis not only did the disease go away but no significant side effects were seen in the mice as per the researchers.

Researchers in Belgrade are also making progress via using other methodologies that involve Ribavirin and Tiazofurin. Administration of ribavirin and tiazofurin attenuated proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue, and thereby prevented myelin destruction. These results are encouraging for the future of MS therapy.